176 related articles for article (PubMed ID: 9824366)
1. The use of imaging studies in the diagnosis and management of thyroid cancer and hyperparathyroidism.
James C; Starks M; MacGillivray DC; White J
Surg Oncol Clin N Am; 1999 Jan; 8(1):145-69. PubMed ID: 9824366
[TBL] [Abstract][Full Text] [Related]
2. Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer.
Nanni C; Rubello D; Fanti S; Farsad M; Ambrosini V; Rampin L; Banti E; Carpi A; Muzzio P; Franchi R
Biomed Pharmacother; 2006 Sep; 60(8):409-13. PubMed ID: 16891093
[TBL] [Abstract][Full Text] [Related]
3. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery.
Rubello D; Mazzarotto R; Casara D
Eur J Nucl Med; 2000 Apr; 27(4):431-40. PubMed ID: 10805117
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation.
Dadparvar S; Chevres A; Tulchinsky M; Krishna-Badrinath L; Khan AS; Slizofski WJ
Eur J Nucl Med; 1995 Nov; 22(11):1330-8. PubMed ID: 8575487
[TBL] [Abstract][Full Text] [Related]
5. 111In-pentetreotide scintigraphy in the post-thyroidectomy follow-up of patients with medullary thyroid carcinoma.
Celentano L; Sullo P; Klain M; Lupoli G; Cascone E; Salvatore M
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):131-3. PubMed ID: 9002771
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic modalities in patients affected by differentiated thyroid carcinoma with high thyroglobulin levels and total body Iodium-131 negative: PET/CT use after recTSH].
Biscontini G; Possa M; Sara R; Milella M; Rossetti C
Minerva Endocrinol; 2004 Dec; 29(4):151-60. PubMed ID: 15765025
[TBL] [Abstract][Full Text] [Related]
7. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
8. RADIOISOTOPE DIAGNOSTIC ALGORITHM FOR THE RELAPSE AND METASTASES DETECTION IN THE IODINE-NEGATIVE DIFFERENTIATED THYROID CANCER.
Solodyannikova OI; Kmetyuk YV; Danilenko VV; Sukach GG
Probl Radiac Med Radiobiol; 2020 Dec; 25():579-591. PubMed ID: 33361863
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
Mucha SA; Kunert-Radek J; Pomorski L
Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of [99mTC]MIBI and [18F]fluorodeoxyglucose for imaging recurrent medullary thyroid cancer and hyperparathyroidism in MEN 2a syndrome.
Roelants V; Michel L; Lonneux M; Lacrosse M; Delgrange E; Donckier JE
Acta Clin Belg; 2001; 56(6):373-7. PubMed ID: 11881324
[TBL] [Abstract][Full Text] [Related]
11. Radioguided surgery of parathyroid adenomas and recurrent thyroid cancer using the "low sestamibi dose" protocol.
Rubello D; Fig LM; Casara D; Piotto A; Boni G; Pelizzo MR; Shapiro B; Sandrucci S; Gross MD; Mariani G;
Cancer Biother Radiopharm; 2006 Jun; 21(3):194-205. PubMed ID: 16918295
[TBL] [Abstract][Full Text] [Related]
12. 99mTc-sestamibi radio-guided surgery of loco-regional 131Iodine-negative recurrent thyroid cancer.
Rubello D; Salvatori M; Casara D; Piotto A; Toniato A; Gross MD; Al-Nahhas A; Muzzio PC; Pelizzo MR
Eur J Surg Oncol; 2007 Sep; 33(7):902-6. PubMed ID: 17267163
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 99mTc(V)-DMSA, 201Tl and 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid.
Ugur O; Kostakğlu L; Güler N; Caner B; Uysal U; Elahi N; Haliloğlu M; Yüksel D; Aras T; Bayhan H; Bekdik C
Eur J Nucl Med; 1996 Oct; 23(10):1367-71. PubMed ID: 8781142
[TBL] [Abstract][Full Text] [Related]
14. [FDG PET scan of metastases in recurrent medullary carcinoma of the thyroid gland].
Szakáll S; Bajzik G; Repa I; Miklovicz T; Dabasi G; Sinkovics I; Esik O
Orv Hetil; 2002 May; 143(21 Suppl 3):1280-3. PubMed ID: 12077916
[TBL] [Abstract][Full Text] [Related]
15. Non-131I-scintigraphy in the treatment and follow-up of thyroid cancer. Single-photon-emitters or FDG-PET?
Grünwald F; Briele B; Biersack HJ
Q J Nucl Med; 1999 Sep; 43(3):195-206. PubMed ID: 10568135
[TBL] [Abstract][Full Text] [Related]
16. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
[TBL] [Abstract][Full Text] [Related]
17. Nuclear medicine imaging procedures in differentiated thyroid carcinoma patients with negative iodine scan.
Rubello D; Saladini G; Carpi A; Casara D
Biomed Pharmacother; 2000 Jul; 54(6):337-44. PubMed ID: 10989970
[TBL] [Abstract][Full Text] [Related]
18. Technetium-99m-sestamibi scanning in recurrent medullary thyroid carcinoma.
Learoyd DL; Roach PJ; Briggs GM; Delbridge LW; Wilmshurst EG; Robinson BG
J Nucl Med; 1997 Feb; 38(2):227-30. PubMed ID: 9025742
[TBL] [Abstract][Full Text] [Related]
19. Clinical approach in patients with metastatic differentiated thyroid carcinoma and negative 131I whole body scintigraphy: importance of 99mTc MIBI scan combined with high resolution neck ultrasonography.
Casara D; Rubello D; Saladini G; Mazzarotto R; Sotti G; Tomasella G; Pelizzo MR
Tumori; 1999; 85(2):122-7. PubMed ID: 10363078
[TBL] [Abstract][Full Text] [Related]
20. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
